Hypercholesterolemia in the Malaysian Cohort Participants: Genetic and Non-Genetic Risk Factors

Genes (Basel). 2023 Mar 15;14(3):721. doi: 10.3390/genes14030721.

Abstract

Hypercholesterolemia was prevalent in 44.9% of The Malaysian Cohort participants, of which 51% were Malay. This study aimed to identify the variants involved in hypercholesterolemia among Malays and to determine the association between genetic and non-genetic risk factors. This nested case-control study included 25 Malay participants with the highest low-density lipoprotein cholesterol (LDL-C, >4.9 mmol/L) and total cholesterol (TC, >7.5 mmol/L) and 25 participants with the lowest LDL-C/TC. Genomic DNA was extracted, and whole-exome sequencing was performed using the Ion ProtonTM system. All variants were annotated, filtered, and cross-referenced against publicly available databases. Forty-five selected variants were genotyped in 677 TMC Malay participants using the MassARRAY® System. The association between genetic and non-genetic risk factors was determined using logistic regression analysis. Age, fasting blood glucose, tobacco use, and family history of hyperlipidemia were significantly associated with hypercholesterolemia. Participants with the novel OSBPL7 (oxysterol-binding protein-like 7) c.651_652del variant had 17 times higher odds for hypercholesterolemia. Type 2 diabetes patients on medication and those with PCSK9 (proprotein convertase subtilisin/kexin type 9) rs151193009 had low odds for hypercholesterolemia. Genetic predisposition can interact with non-genetic factors to increase hypercholesterolemia risk in Malaysian Malays.

Keywords: Malaysian Malay; clinical and environmental factors; genetics; hypercholesterolemia; whole-exome sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Cholesterol, LDL / therapeutic use
  • Diabetes Mellitus, Type 2*
  • Humans
  • Hypercholesterolemia* / epidemiology
  • Hypercholesterolemia* / genetics
  • Proprotein Convertase 9 / genetics
  • Proprotein Convertases / genetics
  • Proprotein Convertases / therapeutic use
  • Risk Factors
  • Serine Endopeptidases / genetics

Substances

  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Cholesterol, LDL
  • Proprotein Convertases
  • Serine Endopeptidases

Grants and funding

This work was supported by a top-down grant from the National Biotechnology Division of the MALAYSIAN MINISTRY OF SCIENCE, TECHNOLOGY AND INNOVATION (MOSTI, ER-05-01-02-MEB001). The Malaysia Genome Institute, MOSTI, administers the grant. Additional funding, including infrastructure and utilities, was provided by UKM.